Effect of Whole Course Neoadjuvant Therapy on Efficacy of Locally Advanced Middle and Low Rectal Cancer and Expression of Malignant Biological Marker Genes in the Lesion
DONG Fei-tian, ZHANG Bo
Department Radiation Oncology,Ankang People's Hospital,Ankang Shaanxi 725000
Abstract 【Objective】To analyze the effect of whole course neoadjuvant therapy on the curative effect of locally advanced middle and low rectal cancer and the expression of malignant biological marker genes in the lesions. 【Methods】A total of 74 patients with locally advanced middle and low rectal cancer who were admitted to our hospital were selected as the research subjects. They were randomly divided into the control group and the observation group,with 37 cases in each group. The control group was given neoadjuvant therapy before surgery,while the observation group was given whole course neoadjuvant therapy. The recent anti-tumor efficacy and lesion resection were compared between the two groups. The expression of biological marker genes in the lesions,drug safety and the prognosis of the two groups were counted as well. 【Results】The objective remission rate of the observation group was higher than that of the control group (P<0.05). The R0 resection rate in the observation group was higher than that in the control group (P<0.05). The relative expression levels of matrix metalloproteinase-11 (MMP-11) and Slug in the surgically removed lesions of the two groups were lower than before treatment (P<0.05). The relative expression levels of MMP-11 and Slug in the observation group were lower than those in the control group (P<0.05). The relative expressions of microtubule-related tumor suppressor genes 1 (MTUS1),matrix metalloproteinase 1 (TIMP1),Runx3,and p53 in surgically removed lesions were higher than before treatment in the two groups (P<0.05); And their relative expression levels in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of hand-foot syndrome,nausea and vomiting,diarrhea,and peripheral neuropathy between the two groups (P>0.05). The three-year survival rates of the observation group was higher than that of the control group.The overall survival rate curves of the two groups were compared,and the difference between the two groups was statistically significant (P<0.05). 【Conclusion】The whole course neoadjuvant therapy can improve the short-term curative effect and surgical R0 resection rate in patients with locally advanced middle and low rectal cancer,inhibit cancer cell invasion,and improve the prognosis.
DONG Fei-tian,ZHANG Bo. Effect of Whole Course Neoadjuvant Therapy on Efficacy of Locally Advanced Middle and Low Rectal Cancer and Expression of Malignant Biological Marker Genes in the Lesion[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(6): 901-904.
[1] REYNGOLD M,NILAND J,TER VEER A,et al. Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at national comprehensive cancer network centers[J].Adv Radiat Oncol,2017,3(1):34-41.
[2] ELLIS C T,COLE A L,SANOFF H K,et al. Evaluating surveillance patterns after chemoradiation-only compared with conventional management for older patients with rectal cancer[J].J Am Coll Surg,2019,228(5):782-791.
[3] SAAD E D,SQUIFFLET P,BURZYKOWSKI T,et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive,early breast cancer in trials of adjuvant trastuzumab for up to 1 year:a systematic review and meta-analysis[J].Lancet Oncol,2019,20(3):361-370.
[4] 黄颖,黄胜辉,池畔,等. 低位直肠癌强化或全程新辅助治疗后保直肠手术的疗效初探[J].中华胃肠外科杂志,2020,23(3):281-288.
[5] 中华医学会消化内镜学分会,中国早期结直肠癌筛查及内镜诊治指南(2014,北京)[J].中华医学杂志,2015,95(28):2235.
[6] EIISEHAUER E A,THERASSE P,BOGAERTS J,et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[7] LEMOINE L.Pathophysiology of colorectal peritoneal carcinomatosis:Role of the peritoneum[J].World J Gastroenterol,2016,22(34):769-707.
[8] DUECK A C,MENDOZA T R,MITCHELL S A,et al. Validity and reliability of the US national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J].JAMA Oncol,2015,1(8):1051-1059.
[9] 翟志伟,张坤宁,王琛,等. 中低位局部进展期直肠癌新辅助治疗与全程新辅助治疗的近期疗效和安全性比较[J].中华胃肠外科杂志,2020,23(3):274-280.
[10] TIE J.Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer:a prospective biomarker study[J].Gut,2019,68(4):663-671.
[11] JANSSEN Q P,BUETTNER S,SUKER M,et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer:a systematic review and patient-level meta-analysis[J].J Natl Cancer Inst,2019,111(8):782-794.
2022, Vol. 39 
